FR-229934
Modify Date: 2025-09-18 17:53:11
FR-229934 structure
|
Common Name | FR-229934 | ||
|---|---|---|---|---|
| CAS Number | 799841-02-4 | Molecular Weight | 468.39700 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H23Cl2N3O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of FR-229934FR-229934 is a PDE V inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction[1]. |
| Name | 3-[(3,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | FR-229934 is a PDE V inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction[1]. |
|---|---|
| Related Catalog | |
| Target |
PDE V |
| References |
[1]. PANDYA J, et, al. Liquid oral formulations for pde v inhibitors. WO2019130052A1. |
| Molecular Formula | C21H23Cl2N3O3S |
|---|---|
| Molecular Weight | 468.39700 |
| Exact Mass | 467.08400 |
| PSA | 92.93000 |
| LogP | 6.60520 |
| 1H-Benzimidazole-6-carboxamide,1-((3,4-dichlorophenyl)methyl)-2-methyl-N-(pentylsulfonyl) |
| UNII-99G2WZ2U4V |